Brian Custer

Brian Custer

Auto-generated profile, based on publicly available information

Brian Custer

Vitalant Research Institute San Francisco California USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2004 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
BCBrian Custer
Brian Custer
SSSean D. Sullivan
Sean D. Sullivan
THThomas K. Hazlet
Thomas K. Hazlet
UIUchenna Iloeje
Uchenna Iloeje
DVDavid L. Veenstra
David L. Veenstra
KKKris V. Kowdley
Kris V. Kowdley
The burden of hepatitis B virus (HBV) disease and efforts to control infection will determine the future size of the population requiring treatment of HBV infection. To quantify the current prevalence of HBV infection and to reexamine the epidemiology of HBV infection, a structured review was conducted that focused on available primary literature for over 30 countries worldwide. The prevalence of chronic HBV infection continues to be highly variable, ranging over 10% in some Asian and Western Pacific countries to under 0.5% in the United States and northern European countries. The current global estimate of the number of HBV infected individuals is 350 million. Routes of transmission include vertical (mother to child or generation to generation through close contact and sanitary habits), early life horizontal transmission (through bites, lesions, and sanitary habits), and adult horizontal transmission (through sexual contact, intravenous drug use, and medical procedure exposure) and are evident to varying degrees in every country. Younger age at acquisition of infection continues to be the most important predictor of chronic carriage. However, the choice of serologic markers, temporal influences, and representativeness of the study population limit comparability of HBV seroprevalence results. HBV vaccination programs will decrease the future global burden of HBV infection and evidence of reduced burden is mounting in country-specific populations, but vaccination programs have still not been implemented in all countries, thereby maintaining reservoirs of infection and continued HBV transmission. Regardless of vaccination, large numbers of persons are infected with HBVor will become infected. Preventing the most severe HBV disease consequences in infected individuals, such as cirrhosis and hepatocellular carcinoma, will require appropriate therapeutic agents.

15 January 2021 in Science
Verified
Journal Article
Open access
PDF file
LBLewis Fletcher Buss
Lewis Fletcher Buss
CJCarlos Augusto Prete Jr.
Carlos Augusto Prete Jr.
CAClaudia M. M. Abrahim
Claudia M. M. Abrahim
AMAlfredo Mendrone
Alfredo Mendrone
TSTassila Salomon
Tassila Salomon
ESEster Cerdeira Sabino
Ester Cerdeira Sabino
Attack rate in Manaus: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) incidence peaked in Manaus, Brazil, in May 2020 with a devastating toll on the city's inhabitants, leaving its health services shattered and cemeteries overwhelmed. Buss et al. collected data from blood donors from Manaus and São Paulo, noted when transmission began to fall, and estimated the final attack rates in October 2020 (see the Perspective by Sridhar and Gurdasani). Heterogeneities in immune protection, population structure, poverty, modes of public transport, and uneven adoption of nonpharmaceutical interventions mean that despite a high attack rate, herd immunity may not have been achieved. This unfortunate city has become a sentinel for how natural population immunity could influence future transmission. Events in Manaus reveal what tragedy and harm to society can unfold if this virus is left to run its course. Science , this issue p. 288 ; see also p. 230

29 May 2007 in Transfusion
Verified
Journal Article
Closed access
PDF file
BCBrian Custer
Brian Custer
ACArtina Chinn
Artina Chinn
NHNora V. Hirschler
Nora V. Hirschler
MBMichael P. Busch
Michael P. Busch
EMEdward L. Murphy
Edward L. Murphy

8 June 2015 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
ESEster C. Sabino
Ester C. Sabino
PLPaula Loureiro
Paula Loureiro
MLMaria Esther Lopes
Maria Esther Lopes
LCLigia Capuani
Ligia Capuani
CMChristopher McClure
Christopher McClure
SGSimone A. Glynn
Simone A. Glynn
Background. A linked donor-recipient study was conducted during epidemics in 2 cities in Brazil to investigate transfusion-transmitted (TT) dengue virus (DENV) by DENV RNA–positive donations. Methods. During February–June 2012, samples were collected from donors and recipients and retrospectively tested for DENV RNA by transcription-mediated amplification. Recipient chart review, using a case (DENV positive)–control (DENV negative and not known to be exposed) design, was conducted to assess symptoms. Results. Of 39 134 recruited blood donors, DENV-4 viremia was confirmed in 0.51% of donations from subjects in Rio de Janeiro and 0.80% of subjects in Recife. Overall, 42 DENV RNA–positive units were transfused into 35 recipients. Of these, 16 RNA-positive units transfused into 16 susceptible recipients were identified as informative: 5 cases were considered probable TT cases, 1 possible TT case, and 10 nontransmissions. The TT rate was 37.5% (95% confidence interval [CI], 15.2%–64.6%), significantly higher than the viremia rate of 0.93% (95% CI, .11%–3.34%) in nonexposed recipients (P < .0001). Chart review did not find significant differences between cases and controls in symptoms or mortality. Conclusions. During a large epidemic of DENV-4 infection in Brazil, >0.5% of donations were RNA positive, and approximately one third of components resulted in TT. However, no significant clinical differences were evident between RNA-positive and RNA-negative recipients.

12 April 2023 in Nature
Verified
Journal Article
Closed access
PDF file
JWJoshua S Weinstock
Joshua S Weinstock
JGJayakrishnan Gopakumar
Jayakrishnan Gopakumar
BBBala Bharathi Burugula
Bala Bharathi Burugula
MUMesbah Uddin
Mesbah Uddin
NJNikolaus Jahn
Nikolaus Jahn
SJSiddhartha Jaiswal
Siddhartha Jaiswal

11 January 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
NRNareg H. Roubinian
Nareg H. Roubinian
SRSarah E. Reese
Sarah E. Reese
HQHannah Qiao
Hannah Qiao
CPColleen Plimier
Colleen Plimier
FFFang Fang
Fang Fang
EHEldad A. Hod
Eldad A. Hod
BACKGROUND: RBC transfusion effectiveness varies due to donor, component, and recipient factors. Prior studies identified characteristics associated with variation in hemoglobin increments following transfusion. We extended these observations, examining donor genetic and nongenetic factors affecting transfusion effectiveness. METHODS: This is a multicenter retrospective study of 46,705 patients and 102,043 evaluable RBC transfusions from 2013 to 2016 across 12 hospitals. Transfusion effectiveness was defined as hemoglobin, bilirubin, or creatinine increments following single RBC unit transfusion. Models incorporated a subset of donors with data on single nucleotide polymorphisms associated with osmotic and oxidative hemolysis in vitro. Mixed modeling accounting for repeated transfusion episodes identified predictors of transfusion effectiveness. RESULTS: Blood donor (sex, Rh status, fingerstick hemoglobin, smoking), component (storage duration, γ irradiation, leukoreduction, apheresis collection, storage solution), and recipient (sex, BMI, race and ethnicity, age) characteristics were associated with hemoglobin and bilirubin, but not creatinine, increments following RBC transfusions. Increased storage duration was associated with increased bilirubin and decreased hemoglobin increments, suggestive of in vivo hemolysis following transfusion. Donor G6PD deficiency and polymorphisms in SEC14L4 , HBA2 , and MYO9B genes were associated with decreased hemoglobin increments. Donor G6PD deficiency and polymorphisms in SEC14L4 were associated with increased transfusion requirements in the subsequent 48 hours. CONCLUSION: Donor genetic and other factors, such as RBC storage duration, affect transfusion effectiveness as defined by decreased hemoglobin or increased bilirubin increments. Addressing these factors will provide a precision medicine approach to improve patient outcomes, particularly for chronically transfused RBC recipients, who would most benefit from more effective transfusion products. FUNDING: Funding was provided by HHSN 75N92019D00032, HHSN 75N92019D00034, 75N92019D00035, HHSN 75N92019D00036, and HHSN 75N92019D00037; R01HL126130; and the National Institute of Child Health and Human Development (NICHD).